Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity.
Saved in:
| Title: | Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity. |
|---|---|
| Authors: | He B; Cancer Microenvironment Laboratory, Harry Perkins Institute of Medical Research, Centre for Medical Research, The University of Western Australia, Perth, WA, Australia., Wood KH; Cancer Microenvironment Laboratory, Harry Perkins Institute of Medical Research, Centre for Medical Research, The University of Western Australia, Perth, WA, Australia., Li ZJ; Cancer Microenvironment Laboratory, Harry Perkins Institute of Medical Research, Centre for Medical Research, The University of Western Australia, Perth, WA, Australia.; Department of Geriatrics and Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Guangdong, P. R. China., Ermer JA; Cancer Microenvironment Laboratory, Harry Perkins Institute of Medical Research, Centre for Medical Research, The University of Western Australia, Perth, WA, Australia., Li J; Cancer Microenvironment Laboratory, Harry Perkins Institute of Medical Research, Centre for Medical Research, The University of Western Australia, Perth, WA, Australia., Bastow ER; Cancer Microenvironment Laboratory, Harry Perkins Institute of Medical Research, Centre for Medical Research, The University of Western Australia, Perth, WA, Australia., Sakaram S; INSiGENe Pty Ltd, UGenome, Tucson, AZ, USA., Darcy PK; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia., Spalding LJ; Harry Perkins Institute of Medical Research, Centre for Medical Research, The University of Western Australia, Perth, WA, Australia., Redfern CT; Harry Perkins Institute of Medical Research, Centre for Medical Research, The University of Western Australia, Perth, WA, Australia., Canes J; SOLTI Cancer Research Group, Barcelona, Spain., Oliveira M; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Prat A; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain., Cortes J; SOLTI Cancer Research Group, Barcelona, Spain.; Medica Scientia Innovation Research (MEDSIR)-Oncoclínicas&Co, Jersey City, NJ, USA.; Medica Scientia Innovation Research (MEDSIR)-Oncoclínicas&Co, Sao Paulo, Brazil.; International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.; IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain., Thompson EW; School of Biomedical Sciences and Centre for Genomics and Personalised Health, Faculty of Health, Queensland University of Technology (QUT) and Translational Research Institute, Brisbane, Australia., Littlefield BA; Eisai Inc., Cambridge, MA, USA., Redfern A; Harry Perkins Institute of Medical Research, Centre for Medical Research, The University of Western Australia, Perth, WA, Australia.; Fiona Stanley Hospital, Perth, WA, Australia., Ganss R; Cancer Microenvironment Laboratory, Harry Perkins Institute of Medical Research, Centre for Medical Research, The University of Western Australia, Perth, WA, Australia. ganss@perkins.uwa.edu.au. |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2025 May; Vol. 17 (5), pp. 1071-1100. Date of Electronic Publication: 2025 Mar 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1757-4684 |
|---|---|
| DOI: | 10.1038/s44321-025-00222-6 |
